At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
tazarotenedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome
In Brief
A Phase 2 clinical trial evaluating tazarotene for Neoplastic Syndrome. Completed, enrolled 36 participants across 2 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying topical tazarotene to see how well it works in treating patients with basal cell skin cancer and basal cell nevus syndrome on the face.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplastic Syndrome
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2004
First PostedJun 2007
Primary CompletionJun 2012
TodayJul 2026
First PostedJun 21, 2007
Enrollment StartJul 1, 2004
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 19.0 years ago
Interventions
tazarotenedrug
Tazarotene is a member of the acetylenic class of retinoids.